We may have reached the point where we have achieved all of the morbidity/mortality benefits that are possible by targeting the renin-angiotensin-aldosterone system (RAAS) in symptomatic heart failure ...

Uptitration of renin-angiotensin-aldosterone system (RAAS) inhibitors was less successful in women than men with acute heart failure (AHF), especially in those with HF with reduced ejection fraction.

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

Unique Characteristics of Hypertension in Blacks That Influence BP Responses to Drugs That Block the Renin-Angiotensin Activating System (RAAS) Blockade of the RAAS in Blacks for Cardiovascular and ...

Hyperkalemia Risk May Be Higher With MRA-RAAS Inhibitor Combo Three studies published in the New England Journal of Medicine on May found no evidence that the use of ACE inhibitors or ...

Finerenone's approval by the FDA to treat type 2 diabetes–associated chronic kidney disease was supported by data from the phase 2 FIDELIO-DKD trial; now, the results of FINEARTS-HF show real-world ...

Hypertension is both a symptom and complication of kidney disease. With C3G and IC-MPGN, blood pressure management is a foundational ‘shield’ that protects kidney function regardless of other ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced chronic kidney disease may benefit from use of angiotensin-converting enzyme inhibitors ...

Discover emerging therapies for hyperkalaemia to enhance chronic kidney disease and heart failure management on World Kidney Day.

Real world data on treatment of chromophobe renal cell carcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...